Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
NCT Number: NCT07216274
This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is a single 3D ultrasound test intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer. Using QTI may be an effective supplemental screening tool, compared to MRI for patients with a high lifetime risk of breast cancer.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Rochester, Minnesota, 55905, United States
In this prospective feasibility study, 25-30 women over the age of 18 years of age with a high lifetime risk of breast cancer >20% (as calculated by a risk assessment model such as Tyrer-Cuzick) and scheduled for a clinically ordered contrast-enhanced breast MRI were included. Exclusion criteria included pregnant or lactating patients, patients with open breast wounds or nipple discharge, patients heavier than 350 pounds, patients unable to lie prone for more than 15 minutes, and patients with a bra size larger than DDD. Enrolled patients were scheduled for a QT examination within 30 days of their clinical MRI. No additional follow-up appointments were required after the QTI exam.
Images from both imaging modalities were reviewed in consensus by four breast radiologists with 2-24 years of experience. Each interpretation was read without the benefit of prior history. The radiologists knew only that the breast MRI was a clinically indicated high-risk screening breast MRI. Since it was possible that one of the radiologists may have interpreted a breast MRI in the study, recall bias was mitigated by waiting about two months before interpreting the cases. The QTI scans were read in a randomized order. Later that same day, the MRI scans were read in randomized order. Up to three findings per breast could be reported for each imaging modality. For each finding, imaging characteristics, size, and location were recorded. A Breast Imaging Reporting and Data System (BI-RADS) score was assigned for each finding.
Weighted Cohen's kappa evaluated agreement between MRI and QTI BI-RADS scores. Unweighted Cohen's kappa used after dichotomizing scores into negative (BI-RADS 1-2) vs positive (BI-RADS 3-5) categories.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Undergo Quantitative Transmission Imaging (QTI) using the QT Ultrasound Breast Scanner
Other names: 3D ultrasound, QTI, QT Ultrasound, Quantitative Transmission Ultrasound (QTUS), Quantitative Transmission Imaging
Ancillary studies
Time frame: Baseline
Assessed by the number of positive findings. For each finding, imaging characteristics, size, and location were recorded. A Breast Imaging Reporting and Data System (BI-RADS) score was assigned for each finding. If biopsies are obtained, then findings will be compared to histopathologic diagnosis.
Mayo Clinic
Other
Quantitative Transmission Imaging Evaluation (QTIE Study) Compared With MRI as Supplemental Screening in Patients With High Lifetime Risk of Breast Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02997553
Adnexal Diseases, Anus Cancer
Vandœuvre-lès-Nancy, France
View Trial DetailsNCT05150652
Breast Cancer, Breast Carcinoma
Lexington, Kentucky, United States
View Trial DetailsNCT03180294
Adnexal Diseases, Breast Carcinoma
Anaheim, California, United States
View Trial DetailsNCT05505175
Breast Cancer, Breast Carcinoma
Salvador, Estado de Bahia, Brazil
View Trial Details